An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of
lenalidomide and a proteosome inhibitor alone or in combination

- Documented refractory or relapsed and refractory multiple myeloma

- Refractory to proteosome inhibitor and lenalidomide, and to last treatment

- Relapsed and refractory patients must have achieved at least a partial response to
previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed
within 6 months, and were refractory to their last treatment

- Measurable disease at screening

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion Criteria:

- Active plasma cell leukemia

- Prior treatment with pomalidomide

- Unable to tolerate thromboembolic prophylaxis while on the study

- Prior autologous stem cell transplant within 12 weeks

- Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C